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Background: Although several studies have investigated the impact of reduced malaria transmission due to
insecticide-treated bed nets (ITNs) on the patterns of morbidity and mortality, there is limited information on their
effect on parasite diversity.
Methods: Sequencing was used to investigate the effect of ITNs on polymorphisms in two genes encoding
leading Plasmodium falciparum vaccine candidate antigens, the 19 kilodalton blood stage merozoite surface
protein-1 (MSP-119kDa) and the Th2R and Th3R T-cell epitopes of the pre-erythrocytic stage circumsporozoite
protein (CSP) in a large community-based ITN trial site in western Kenya. The number and frequency of
haplotypes as well as nucleotide and haplotype diversity were compared among parasites obtained from
children <5 years old prior to the introduction of ITNs (1996) and after 5 years of high coverage ITN use (2001).
Results: A total of 12 MSP-119kDa haplotypes were detected in 1996 and 2001. The Q-KSNG-L and E-KSNG-L
haplotypes corresponding to the FVO and FUP strains of P. falciparum were the most prevalent (range 32–37%),
with an overall haplotype diversity of > 0.7. No MSP-119kDa 3D7 sequence-types were detected in 1996 and the
frequency was less than 4% in 2001. The CSP Th2R and Th3R domains were highly polymorphic with a total of 26
and 14 haplotypes, respectively detected in 1996 and 34 and 13 haplotypes in 2001, with an overall haplotype
diversity of > 0.9 and 0.75 respectively. The frequency of the most predominant Th2R and Th3R haplotypes was
14 and 36%, respectively. The frequency of Th2R and Th3R haplotypes corresponding to the 3D7 parasite strain
was less than 4% at both time points. There was no significant difference in nucleotide and haplotype diversity in
parasite isolates collected at both time points.
Conclusion: High diversity in these two genes has been maintained overtime despite marked reductions in
malaria transmission due to ITNs use. The frequency of 3D7 sequence-types was very low in this area. These
findings provide information that could be useful in the design of future malaria vaccines for deployment in
endemic areas with high ITN coverage and in interpretation of efficacy data for malaria vaccines based on 3D7
parasite strains.
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Malaria caused by Plasmodium falciparum continues
to place a heavy burden on the health and economic
development of populations in endemic areas [1]. Over
the last decade, increased funding for malaria control
has resulted in rapid scale-up of key interventions
including insecticide-treated bed nets (ITNs) in many
areas [2] ITNs have been shown to reduce malaria trans-
mission by 70-90%, leading to significant reductions in
human-vector contact, the number of infectious mosquito
bites [3,4] and the force of infection [5]. Previous studies
have shown that the intensity of malaria transmission is
an important determinant of the malaria burden in the
population, the rates of acquisition of protective immunity
and the dynamics of parasite dispersal in mosquito vectors
[6]. Based on these observations, fears have been expressed
that reduced transmission and exposure to malaria par-
asites could modify the vector-host-parasite interaction,
delay the acquisition of protective immunity and result
in a shift in the burden of severe disease and mortality
[7]. Studies designed to investigate whether sustained
use of ITNs during infancy leads to an increase in
malaria-related morbidity and mortality in older chil-
dren demonstrated that there is no shift in the malaria
burden [8,9]. The few studies that have assessed the
impact of ITNs on acquired immunity by comparing
antibody responses to malaria antigens in children with
or without ITNs have been inconclusive [10-14].
However, there is limited information on the impact of
transmission reduction as a result of sustained use of
ITNs on the genetic diversity of P. falciparum parasites.
Malaria transmission intensity has been shown to play
an important role in determining the genetic diversity of
malaria parasites [15]. This is because malaria parasites
undergo an obligate sexual reproduction in the mosquito
vector, thereby creating an opportunity for generation of
parasite diversity through intragenic recombination and
re-assortment of genetic material during meiosis [16]. In
areas of high transmission, both the numbers of infected
hosts and the carriage of multiple-clone infections per
individual are generally higher, therefore increasing the
probability for mosquito vectors to obtain genetically
diverse gametocytes during blood feeding [16,17]. This
in turn increases the chance of out-breeding and higher
rates of genetic recombination. These observations have
lead to the hypothesis that significant reduction in the
intensity of malaria transmission could lead to a decrease
in the mean number of multiple-genotype infections in
humans, which could decrease the frequency of recom-
bination resulting in a reduction in the level of genetic
diversity [16].
A previous study conducted by this same group using
neutral microsatellite (MS) markers has shown an over-
all stability in genetic diversity of P. falciparum after fiveyears of high ITN coverage except for a significant MS
locus specific change associated with gametocytes [18].
The current study was designed to investigate the impact
of sustained use of ITNs on the genetic diversity of two
leading P. falciparum vaccine candidate antigens during
the same study period and in the same study area in
western Kenya. This study assessed single nucleotide
polymorphisms (SNPs) in genes encoding the relatively
conserved B-cell epitopes of the blood-stage 19-kDa
region of the merozoite surface protein (MSP-1 19kDa)
and the highly polymorphic pre-erythrocytic-stage circum-
sporozoite protein (CSP) Th2R and Th3R T-helper cell
epitopes. These two genes were chosen for assessment
because their polymorphism is thought to be partly
driven by the host immune pressure and are likely to
be subjected to the diversifying effects of changes in
malaria transmission [15]. Monitoring the genetic diversity
of leading P. falciparum vaccine candidate antigens over
time will help better understand the relationship between
transmission intensity as malaria interventions are scaled
up and the diversity of parasite antigens that are under
selection pressure. In addition, these data will be useful
in interpreting efficacy data of malaria vaccines that are
based on 3D7 sequences.
The merozoite surface protein-1 (MSP-1) is the major
protein on the surface of asexual blood stages of the
malaria parasites [19]. The MSP-1 195-kDa protein is
synthesized during schizont maturation and undergoes
two rounds of proteolytic cleavage leaving a 19-kDa
fragment (MSP-1 19kDa) adhering on the surface of mero-
zoites during erythrocyte invasion [20]. The MSP-1 19kDa
contains two cysteine-rich epidermal growth factor (EGF)-
like motifs that play an important role in erythrocyte
invasion, making it an ideal target of inhibitory antibodies
for blocking parasite invasion of erythrocytes [20] and
therefore an ideal candidate for a malaria vaccine.
Although MSP-1 is characterized by extensive polymor-
phisms, the 19-kDa region is relatively conserved apart
from five key non-synonymous SNPs corresponding to
amino-acid positions 1644 (Q/E), 1691 (K/T), 1699 (S/N),
1700 (N/S), and 1701 (G/R). Intragenic recombination
and single-nucleotide mutations are thought to play a
role in generation of allelic variation in MSP-1 19kDa
[21,22]. Several malaria blood-stage vaccine candidates
containing MSP-1 19kDa have undergone field trials with
varied results [23].
The CSP is the predominant protein found on the
surface of sporozoites [24]. The P. falciparum csp gene
encodes a protein of approximately 420 amino acid res-
idues with a molecular weight of 58 kDa consisting of
two non-repetitive regions at the 5' and 3' ends and a
variable central region that encodes immunodominant
B-cell epitopes with multiple repeats of four amino acid
motifs [25]. The C-terminal end of the gene contains
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and Th3R, flanking the conserved RII region [25]. The
CSP has been the subject of extensive research for the
development of a vaccine against pre-erythrocytic stages
of malaria parasites [26]. The central repeat and C-ter-
minal regions of the CSP forms part of the most clinically
advanced malaria vaccine candidate RTS,S that is cur-
rently undergoing a phase III clinical trial in several
African countries [27,28]. Studies conducted in areas of
different transmission settings have shown an association
between the genetic diversity in the csp gene and malaria
transmission, with the highest diversity observed in
parasite populations from Africa [15].
The current study investigated the impact of transmission
reduction due to the use of ITNs on the genetic diversity
of genes encoding two P. falciparum polymorphic vaccine
candidate antigens in 1996 before and 5 years after the
deployment of ITNs in an area of western Kenya
holoendemic for malaria. Prior to the ITN trial, malaria
transmission in this area was intense and perennial
with an estimated entomologic inoculation rate (EIR) of
60 to 300 infective bites per person per year [29]. It
was estimated that malaria transmission in this area
reduced by 95% after the introduction of ITNs [9].
Methods
Study area and population
This study was conducted in the context of a community-
based cluster randomized controlled trial of ITNs in
western Kenya that consisted of two phases. Phase 1
was designed to assess the impact of ITNs on all-cause
mortality in young children while phase 2 consisted of
an extended surveillance to monitor whether sustained
use of ITNs during infancy increased all-cause morbidity
and mortality in older children. The characteristics of
the study area, design of the ITN trial and the two-year
surveillance have been described in detail elsewhere
[9,30]. Briefly, a randomized ITN trial was conducted
between January 1997 and March 1999 in Rarieda Division
(Asembo) where malaria is holoendemic and transmission
occurs throughout the year.
At the end of the two-year trial period, ITNs were
also distributed to all control villages and monitoring
continued for an additional two years until March 2001.
Throughout the two phases, annual cross-sectional
surveys were conducted in 60 villages to collect infor-
mation on malaria morbidity indicators. During the
surveys finger stick blood samples were taken among
children aged below five years. In addition, entomologic
indices were collected throughout the two phases of
the trial to estimate malaria transmission. During phase
1 of the trial there was a 72% reduction in the density
of indoor-resting blood-fed Anopheles in the houses
with ITNs and in the second phase, villages with ITNsexperienced a 77% reduction in Anopheles densities com-
pared with villages in an adjacent area [9]. In addition,
parasite prevalence in children under the age of five
decreased from 70% prior to the ITN trial to 34% in
2001 [9,31]. The use of ITNs before the trial was less
than 5% but increased to 65.9% and 82.5% in phase 1
and 2 respectively [9].
The blood samples used in the current study were
collected in October and November 1996, before phase
1 of the ITN trial and in May and June in 2001, 5 years
after introduction of ITNs in phase 1. Microscopically
confirmed malaria positive blood samples were randomly
selected from those collected in the 1996 cross-sectional
survey and matched by village with samples collected
in the 2001 survey.
Laboratory procedures
Sample collection
During each survey, 250-500 μl of blood was collected
from each child by finger-stick into EDTA microtainers
(Becton Dickinson, Franklin Lakes, NJ). Blood samples
were transported in cool boxes to the central laboratory
in Kisian, about 50 km from the field site and stored at
4°C until further processing. All samples were labelled
with unique identification numbers that could not be
linked to the randomization status of the sampled children.
Erythrocytes were separated from plasma by centrifugation
at 700 G for 5 min. Packed red blood cells (RBCs) were
aliquoted into sterile vials and stored at -70°C until the day
of DNA isolation.
DNA extraction and PCR amplification
Parasite genomic DNA was extracted using the QIAamp®
DNA Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The CSP gene was ampli-
fied by polymerase chain reaction (PCR) in a 25 μl reac-
tion mixture containing 1 μl of DNA, 0.2 μM of forward
and reverse primers CSP-F: ACAATCAAGG TAATGGA
CAAGG and CSP-R:GGATTAATAATGGTATTATCCTT
CT, 1× TBE buffer, 2.0 mM MgCl2, 250 μM dNTPs,
and 2.5 U Taq DNA polymerase (Promega Corporation,
Madison, Wisconsin, USA). The cycling conditions
were as follows: 95°C for 5 min, 58°C for 2 min and 72°C
for 2 min for 1 cycle, then 94°C for 1 min, 58°C for 2 min
and 72°C for 1 min for 32 cycles followed by 10 min
extension at 72°C. The primers were designed to hybridize
to conserved regions covering the Th2R, Th3R and the
universal T-cell epitopes, resulting in a 354 base-pair
fragment. The MSP-119-kDa gene was amplified in a 25 μl
reaction mixture containing 1 μl of DNA, 0.2 μM of two
forward primers- 5’ CGTTTTATCTAATTTACTTGATG
GAA 3’(K16F), specific for K1 and 5’ CCTAATACAATAA
TATCAAAATTAATTGA 3’ (M16F), specific for MAD-20
and a common reverse primer 5’ TTAAGGTAACATAT
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dNTPs, and 1.25U Taq DNA polymerase with the fol-
lowing cycling conditions: 91°C for 1.5 min, then 91°C
for 30 sec, 50°C for 40 sec and 70°C for 40 sec for
40 cycles followed by 5 min extension at 72°C. PCR
was carried out in a GeneAmp® PCR System 9700
(Biosystems, PE, USA).Sequencing
The PCRs products were cleaned using CentriSep spin
columns (Princeton Separations, Adelphia, NJ) according
to the manufacturer instructions. Sequencing reactions
were carried out using forward and reverse primers in
separate reactions by the BigDye® Terminator v3.1 Cycle
Sequencing Kit and analysed in an ABI 3100 DNA
Sequencer (Applied Biosystems, Foster City, CA). The
ChromasPro, version 2.31 software (Technelysium Pty
Ltd, Queensland, AU) was used to align the sequences.
Each sequence was manually checked for true base call-
ing and samples with doubtful sequencing results were
repeated.Data analysis
The MSP-119-kDa sequences were aligned with known
sequences from the P. falciparum genome database at the
National Center for Biotechnology Information (NCBI)
using the P. falciparum clone 3D7 as the reference
sequence while the CSP Th2R and Th3R sequences
were aligned using the 3D7 and 7G8 clones. Molecular
analyses were conducted using MEGA version 4 [32]
and DNA Sequence Polymorphism, version 4.0 [33]
softwares to create haplotypes. Differences in the fre-
quency of haplotypes between baseline and post-ITN
intervention surveys were compared by Chi-square test.
The genetic diversity parameters including nucleotide
diversity (π), number of haplotypes (NHap) and haplo-
type diversity (HapDiv) in parasite populations at base-
line and at post ITN intervention were determined
using the sequence polymorphism softwares, DnaSP v5
[34], MEGA version 4 [32] and ARLEQUINS suite ver
3.5 [35]. Nucleotide sequences reported here are available
in GeneBank under accession numbers BankIt1630040:
KF158421 - KF158555 (Pfmsp-119-kDa) and BankIt16303
20: KF158556 - KF158712 (Pfcsp C-terminal domain).Ethical approval
The study was approved by the Ethical Review Commit-
tee of the Kenya Medical Research Institute, Nairobi,
Kenya and the Institutional Review Board of the Cen-
ters for Disease Control and Prevention (CDC) Atlanta,
Georgia, USA.Consent
Written informed consent was obtained from the patient’s
guardian/parent/next of kin for the publication of this
report and any accompanying images.
Results
Frequency of MSP-119-kDa haplotypes
A total of 136 parasite samples were successfully se-
quenced for the gene encoding MSP-119-kDa, 58 at baseline
and 78 in 2001. Overall, seven non-synonymous amino
acid replacements were detected at positions 1644 (Q-E),
1691 (K-T), 1695 (E-K), 1699 (S-N), 1700 (S-N), 1701
(G-R) and 1716 (L-F). Based on the amino acid replace-
ments, a total of 12 MSP-119-kDa haplotypes were detected
in the study area in 1996 and 2001. Out of these, 3 hap-
lotypes, Q-TESNGL, E-TESSGL and E-TESNGF are new
and have not been reported before. Out of the 12 haplo-
types identified, 8 haplotypes were observed in the 1996
and 2001 surveys while 4 haplotypes were observed at
only one time point, 2 in 1996 and 2 in 2001. The E-
KSNGL and Q-KSNGL haplotypes corresponding to
the FUP-Uganda PA and FVO-Wellcome strains of P.
falciparum had the highest prevalence in 1996, 37 and
32% respectively, and in 2001 it was, 37% for both
strains (Figure 1). The frequency of all the other haplo-
types was low, ranging from 2-7% at both time points.
The frequency of the MSP-1 haplotype (E-TESSRL) corre-
sponding to the 3D7 strain, the sequence contained in
malaria vaccine candidates that are at various stages of
development was less than 4% in 2001 and none was
detected in 1996.
Genetic diversity of the MSP-119-kDa haplotypes
The genetic diversity of the MSP-119-kDa in parasite
populations in 1996 and 2001 were comparable, with a
nucleotide diversity (π) of 0.0038 and 0.0033 respect-
ively (Table 1). Likewise, there was no significant differ-
ence in the number of haplotypes (NHap) or haplotype
diversity (HapDiv) in parasite isolates collected in 1996
and 2001.
Frequency of CSP Th2R and Th3R haplotypes
At both surveys, a total of 157 (68 in 1996 and 89 in
2001) out of 175 parasite samples yielded interpretable
sequences and were included in the analysis. Overall,
there was a high diversity on the CSP C-terminal domain
containing immunodominant T-cell Th2R and Th3R
epitopes (Figures 2 and Figure 3). At the Th2R domain,
a total of 26 and 34 haplotypes were detected in 1996
and 2001 surveys respectively, and for the Th3R domain,
these were 14 and 13 haplotypes. Overall, there was a high
fluctuation in the frequency of both the Th2R and Th3R
haplotypes at both time points with some haplotypes
detected at baseline and not in 2001 and vice versa
Figure 1 The frequency of MSP-119-kDa haplotypes at baseline (1996) and following 5 years of community-wide ITN use (2001).
* Indicates the haplotype sequence corresponding to the 3D7 P. falciparum strain.
Kariuki et al. Malaria Journal 2013, 12:295 Page 5 of 10
http://www.malariajournal.com/content/12/1/295(Figures 3A and B). Two Th2R haplotypes, QHIEKY
LKTIQNSL and QHIEQYLKTIQNSL, had the highest
frequency in 1996; 14 and 13% respectively; and 2001, 7
and 12% respectively. The frequency of all the other
Th2R haplotypes was less than 5% at both time points.
At the Th3R domain, the NKPKDEQDYEND and NKP
KDEQDYAND haplotypes had the highest frequencies,
in 1996, 30% for both haplotypes; and in 2001, 31 and
36% respectively. The frequency of all the other Th3R
haplotypes was less than 10%. At both Th2R and Th3R
domains, the frequencies of haplotypes corresponding
to the 3D7 strain of P. falciparum were less than 4% at
both time points.Table 1 Genetic diversity at the MSP-119-kDa domain at
baseline (1996) and following 5 years of community-wide
ITN use (2001)
MSP-119-kDa domain
Survey n π NHap HapDiv
1996 58 0.0038 (0.0005) 11 0.782
2001 78 0.0033 (0.0004) 9 0.721
n, Number of samples sequenced per cross-sectional survey.
π, Nucleotide diversity (standard deviation).
Nhap, No of haplotypes.
HapDiv, Haplotype diversity.Genetic diversity of the CSP Th2R and Th3R haplotypes
The genetic diversity of the CSP gene at the Th2R and
Th3R domains are shown in Tables 2 and Table 3. Similar
to the high number of haplotypes detected in 1996 and
2001, there was a high diversity in both domains at the
two time points. The genetic diversity was higher in Th2R
than the Th3R region as seen in the higher haplotype and
nucleotide diversity (HapDiv and π) at both time points.
There was no significant difference in the genetic diversity
at both T cell epitopes between parasite isolates collected
in the two surveys.
Discussion
For the gene encoding the blood stage MSP-119-kDa anti-
gen, a total of 12 haplotypes were identified at both
baseline and 5 years after distribution of ITNs in this
area. This number is consistent with findings from previ-
ous studies conducted in our study area and in other
malaria holoendemic areas of Africa showing a higher
number of MSP-119-kDa haplotypes (range 6-15) in areas
of high transmission and high EIRs ranging from 50 to
600 infective bites person per year, [21,22,36] compared
with fewer haplotypes (range 1-3) in areas of lower
transmission and EIRs of less than 10 infective bites per
person per year [37,38]. The E-KSNGL haplotype corre-
Figure 2 The frequency of most common Th2R CSP haplotypes at baseline (1996) and following 5 years of community-wide ITN use
(2001). * Indicates the haplotype sequence corresponding to the 3D7 P. falciparum strain.
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Q-KSNGL corresponding to the FVO-Wellcome strain
were the most predominant MSP-119-kDa haplotypes in
1996 and 2001. These two haplotypes have been reported
at high frequencies in previous studies conducted in this
area and other regions in Africa. In a study conducted in
the same area in 1998, Qari et al reported frequencies of
42 and 21% for the E-KSNGL and Q-KSNGL haplotypes
respectively [21]. Similarly, frequencies of 36 and 38%
for the E-KSNGL and Q-KSNGL haplotypes respectively
have been reported in a site near this study area [39]. In
the current study, the frequency of other MSP-119-kDa
haplotypes was very low.
There was no significant change overtime in the fre-
quency, the number of MSP-119-kDa haplotypes, haplo-
type diversity and π. The stability in the frequency of
haplotypes and the genetic diversity overtime, suggests
that the MSP-119-kDa gene could be under balancing
selection as documented in previous studies [40-42].
Similar levels of genetic stability have been reported in
a malaria holoendemic area of Tanzania where poly-
morphic sites of the gene encoding the MSP-119-kDa
gene was relatively stable for a period of 15 years [22].
This contrasts with significant temporal variations in
the frequencies of MSP-119-kDa haplotypes reported in astudy conducted in an area of low malaria transmission
[43]. This difference has been explained to be due to
the relatively low rates of meiotic recombination or strong
selection pressure that maintain a clonal structure in
parasite populations from areas of low transmission,
while the reverse is true in areas of high transmission
[43]. Therefore, the relative stability of MSP-119-kDa
haplotypes observed in this study over a period of
5 years suggests that the rates of meiotic recombination
in parasite populations in this area remain high despite
the significant reduction in transmission associated
with the deployment of ITNs.
The frequency of the MSP-1 haplotype (E-TESSRL)
corresponding to the 3D7 strain of P. falciparum was
not detected at baseline and was less than 4% in 2001.
Low frequencies of MSP-1 3D7 sequence-types has been
reported in previous studies conducted in different malaria
transmission areas [21,36,43,44]. It has been suggested
that the low frequency of haplotypes corresponding to
the 3D7 strain of P. falciparum could compromise the
efficacy of MSP-1 vaccines that are based on the 3D7
clone. For example, a recent phase IIb trial of an MSP-142-
based vaccine candidate derived from the 3D7 clone of P.
falciparum in children aged 12-27 months in a nearby
study area reported an overall vaccine efficacy of 5.1%
Figure 3 The frequency of the most common Th3R CSP haplotypes at baseline (1996) and following 5 years of community-wide ITN
use (2001). * Indicates the haplotype sequence corresponding to the 3D7 P. falciparum strain.
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multiplicity of infections and diversity of MSP-142 gene
in this area [45]. Similarly, the variable success of MSP-1
vaccines that are at various stages of development includ-
ing those based on FVO alleles has been attributed to
polymorphisms in P. falciparum antigens [46]. Therefore,
data on the genetic diversity of parasite populations circu-
lating in area similar to that obtained in the current study
provide important baseline information that could be
useful in planning and interpreting data on the efficacy
of vaccines that are based on polymorphic antigens
such as MSP-1.
For the highly polymorphic Th2R and Th3R T-helper
cell epitopes, there were 26 and 34 Th2R haplotypes atTable 2 Genetic diversity at the CSP Th2R epitope at
baseline (1996) and following 5 years of community-wide
ITN use (2001)
CSP Th2R
Survey n π NHap HapDiv
1996 68 0.0594 (0.00039) 26 0.943
2001 89 0.0613 (0.00035) 34 0.956
n, Number of samples sequenced per cross-sectional survey.
π, Nucleotide diversity (standard deviation).
Nhap, No of haplotypes.
HapDiv, Haplotype diversity.baseline and 5 years post-ITNs respectively and 14 and
13 Th3R haplotypes at the two time points. These findings
are consistent with results of an earlier study conducted in
the same area that reported 29 and 16 haplotypes for the
Th2R and Th3R epitopes respectively [47]. This suggests
that the CSP haplotypes circulating in this area have
remained relatively stable for an extended period. This
contrasts sharply with findings from areas of low malaria
transmission which show that 1 or 2 haplotypes are pre-
dominant with frequencies as high as 80% [48]. In this
study, the most frequent Th2R and Th3R haplotypes were
14% and 30% at baseline and 13 and 36% in 2001. Other
haplotypes were rare with a prevalence of less than 10%.
The frequency of haplotypes corresponding to the 3D7Table 3 Genetic diversity at the CSP Th3R epitope at
baseline (1996) and following five years of
community-wide ITN use (2001)
Th3R
Survey n π NHap HapDiv
1996 68 0.0549 (0.0068) 14 0.811
2001 89 0.0437 (0.0052) 13 0.779
n, Number of samples sequenced per cross-sectional survey.
π, Nucleotide diversity (standard deviation).
Nhap, No of haplotypes.
HapDiv, Haplotype diversity.
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vaccine candidate that is currently undergoing a phase
3 efficacy trial in areas of different transmission inten-
sities in Africa [27,28] is derived from the 3D7 strain of
P. falciparum and comprises part of the repeat, Th2R
and Th3R regions of the CSP. Although there is no evi-
dence that the observed efficacy of the RTS,S vaccine is
sequence-dependent [49,50] the information obtained
in this study could be useful in the interpretation efficacy
data of the RTS,S vaccine and other CSP-based malaria
vaccines that are based on the 3D7 parasite strain in
this area. This information could also inform the design
of future vaccines for deployment in areas of high and
perennial malaria transmission.
The high genetic diversity in the T-cell epitopes of the
CSP gene was also apparent when measured by haplo-
type diversity and π. These findings are consistent with
previous studies that have documented high genetic
diversity in ThR2 and Th3R regions of CSP in parasite
populations from regions of high malaria transmission
[47,51,52]. This contrasts with low genetic diversity in
parasite populations from areas of low malaria transmis-
sion of Brazil [52], Papua New Guinea [48,53], India [54]
and Iran. In addition, similar to previous studies, the
current study also shows that the Th2R region is more
diverse than the Th3R region, suggesting that the Th2R
region could be under strong selective pressure unre-
lated to the intensity of malaria transmission. Similar to
MSP-119-kDa gene, there was no significant difference in
genetic diversity of the two T-cell epitopes in parasite
populations at baseline and 5 years post-ITN intervention.
The relative stability in the diversity of Th2R and Th3R
regions has also been documented over a period of 5 years
in a region of low transmission in Vietnam [55]. Taken
together, our results indicate that transmission reduction
due to sustained use of ITNs over a period of five years
had no impact on the genetic diversity of the highly poly-
morphic Th2R and Th3R epitopes of the CSP gene.
Several factors have been suggested to play a role in the
generation and maintenance of parasite diversity including
transmission intensity, immune-mediated pressure, para-
site positive rates, rates of multiple-genotype infections
and patterns of antimalarial drug use [22]. In the current
study, the sustained use of ITNs over a period of five years
in a region of western Kenya with intense and perennial
malaria transmission had no significant impact on parasite
diversity of the two polymorphic P. falciparum genes.
A few factors could explain this observation. Firstly,
despite a decline in transmission intensity following the
deployment of ITNs, parasite prevalence remained rela-
tively high and 50% of children sleeping under ITNs were
parasitaemic during phase 1 of the ITN trial (1996-1998)
[31], and > 30% of post neonatal infants (one to 11 months)
were parasitaemic during phase 2 of the trial (1999-2001)[9]. Similarly, cross-sectional surveys conducted 2-4 years
after introduction of ITNs showed that up to one third of
infants sleeping under ITNs were parasitaemic [9]. Sec-
ondly, although the target of the ITN trial was to cover
all the sleeping spaces and efforts were made to moni-
tor adherence, a significant proportion of people did
not sleep under ITNs and remained exposed to malaria
[56]. In phase 1 of the trial which distributed ITNs only
to half of the villages, adherence to the use of ITNs was
65.9% and increased to 82.5% during the second phase
when ITNs were distributed to the villages that acted
as control in phase 1 [9]. Collectively, these epidemio-
logical findings and the results obtained in the current
study on stability of parasite genetic diversity suggest that
exposure to malaria parasites in western Kenya remains at
a level that allows genetic mixing of diverse parasite genes
despite transmission reduction due to ITNs. Furthermore,
it is possible that any observable impact of vector control
interventions on genetic diversity of malaria parasites
might require reduction of transmission intensity by
more than the 90% reported in the ITN trial [4]. It is
also conceivable that in areas of intense transmission,
the impact of transmission reduction on parasite diver-
sity will take greater reduction in transmission and for
a much longer period than the 5-year period used to
select sample for analysis in the current study or
15 years as shown in a previous study in Tanzania [22].
The short time period used in comparing parasite diver-
sity after introduction of ITNs is a limitation in this study.
The antigens used in this study could also be a limitation.
Although the antigens used have been shown in previous
studies to be under strong immunological pressure, it is
likely that detection of changes in parasite diversity as a
result of transmission reduction requires antigens that
are highly sensitive to transmission dynamics. Lastly,
although the study compared parasite diversity before
and after introduction of ITNs, the absence of a contem-
poraneous area without ITNs for comparison is also a
limitation in the current study.
Conclusions
Data obtained in this study show that the MSP-119kDa
haplotypes have remained stable overtime and transmis-
sion reduction due to ITNs had no impact on the diversity
of MSP-119kDa and the Th2R and Th3R domains of the
CSP. The results also show that the CSP Th2R region is
more diverse than the Th3R region and could be under
strong selective pressure unrelated to the intensity of
malaria transmission. The information on low frequency
of 3D7 clone could be useful in interpreting data on the
efficacy of malaria vaccines based on the 3D7 parasite
strain in areas of stable malaria transmission and in
informing the development of future malaria vaccines
for deployment in areas of high transmission.
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